CDX2 and prostate carcinoma: As shown in Table 2, VDR Cdx2 polymorphism was not significantly associated with prostate cancer risk in the pooled meta-analysis of all the eligible studies (homozygote model: AA vs. GG: OR = 1.11, 95 % CI = 0.93–1.33, P = 0.23; heterozygote model: GA vs. AA: OR = 0.97, 95 % CI = 0.88–1.06, P = 0.53; dominant model: AA + GA vs. GG: OR = 0.99, 95 % CI = 0.91–1.08, P = 0.80, Fig. 1; recessive model: AA vs. GA+ GG: OR = 1.12, 95 % CI = 0.95–1.31, P = 0.16).